When our patients start HD, everything gets filtered, except the debate on beta-blocker dialyzability
Read #NephJC short about new target emulation trial, suggesting the non-dialyzables may be doing some heavy MACE-lifting
✍️By @DrPallaviPrasad
https://t.co/P5RnixeHTV
Stopping Renin-Angiotensin System Inhibitors (RASi) in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study ca. 2021 from @JASN_News@FuEdouard#Nephpearls#Cardiorenal#NephJC
👉 https://t.co/sIyNUmDBev
1/ 🚨 NEW #BeyondJournalClub with @NEJMGroup: REVISE Trial
Do PPIs reduce the risk of clinically important upper GI bleeding? ⤵️
🖥️: https://t.co/dJnq8p9VDE
Sponsor: @FreedMedicalAI
@edgarvlermamd@brian_rifkin@ACMCIMRes With Tunneled SB cath which is typcial alternative to PICC for CKD patients, some facilities declined to accept patients with SB cath. So need to coordinate with case manager too
I'm excited to see this true GFR measurement drug/device nearing FDA approval.
Imagine injecting a inert fluoroprobe, slapping a pulse-ox like monitor on them and in less than 1 hr knowing their mGFR. You could also monitor for changes in mGFR over12-24h.
https://t.co/qhyS4e7sN1
Report of our working group on the aHUS/TMA nomenclature is out!!
Supported by @nkf, this is an initial effort to standardize terminology to align with advancements in our understanding of the underlying pathophysiology of the various TMAs.
https://t.co/0HoMmOcIk2
No one remains a trainee forever, and unresolved issues in the system have led to the collapse of South Korea's residency program. @JournalofGME
https://t.co/80wKl09y5s